Skip to main content
Viatris10-Q: Competitor named

Viatris in payment dispute with Pfizer over opioid-related liabilities

What happened

Viatris is facing a financial claim from partner Pfizer related to a cost-sharing agreement for opioid litigation losses, which Viatris disputes. This creates significant financial uncertainty and legal distraction, increasing the need for risk management and financial forecasting solutions.

Source

SEC EDGARAug 6, 2026

Quarterly report (Form 10-Q)

Viatris 10-Q

Filing excerpt

In June 2026, the Company received a letter from Pfizer inquiring about the Company’s plan for payment to Pfizer under the foregoing agreement. The Company disagrees that the payment Pfizer requests is owed. Any loss to the Company as a result of the foregoing disagreement could have an adverse impact on Viatris.

sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htmRead the full source

Other signals in this filing (6)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Competitor named

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/30
Filed
Aug 6, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
57% (Portion of opioid-related losses Viatris agreed to pay Pfizer)

Details

CIK
1792044
Accession number
0001792044-26-000041
Timeframe
Current quarter
Filing year
2026
Fiscal year
0
Why it matters
Competitive intelligence
Signal category
Market

Topics and mentions

Competitors

  • Pfizer

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
90%
Sentiment
Negative
Detected
Aug 11, 2026
signal_type
sec-10q
signal_subtype
competitorNamed

Use this data

Get every 10-Q signal for Viatris and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b546a347-55ac-4824-b586-9a7e344e33a9 returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.

{
  "signal_id": "b546a347-55ac-4824-b586-9a7e344e33a9",
  "signal_type": "sec-10q",
  "signal_subtype": "competitorNamed",
  "detected_at": "2026-08-11T08:10:22.107+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "detail": "Viatris is facing a financial claim from partner Pfizer related to a cost-sharing agreement for opioid litigation losses, which Viatris disputes. This creates significant financial uncertainty and legal distraction, increasing the need for risk management and financial forecasting solutions.",
    "metrics": {
      "pct": 0.57,
      "timeframe": "current_quarter",
      "pct_context": "Portion of opioid-related losses Viatris agreed to pay Pfizer",
      "dollar_context": "Disputed payment related to opioid losses"
    },
    "summary": "Viatris in payment dispute with Pfizer over opioid-related liabilities",
    "excerpts": "In June 2026, the Company received a letter from Pfizer inquiring about the Company’s plan for payment to Pfizer under the foregoing agreement. The Company disagrees that the payment Pfizer requests is owed. Any loss to the Company as a result of the foregoing disagreement could have an adverse impact on Viatris.",
    "relevance": 0.9,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htm",
    "filing_date": "2026-08-06",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Competitive intelligence",
    "signal_category": "market",
    "regions_mentioned": [
      "U.S."
    ],
    "competitors_mentioned": [
      "Pfizer"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.